1.03
price down icon3.74%   -0.04
after-market アフターアワーズ: 1.02 -0.01 -0.97%
loading
前日終値:
$1.07
開ける:
$1.07
24時間の取引高:
1.39M
Relative Volume:
1.11
時価総額:
$194.60M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-0.6319
EPS:
-1.63
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-24.82%
1か月 パフォーマンス:
-26.95%
6か月 パフォーマンス:
-41.31%
1年 パフォーマンス:
+113.91%
1日の値動き範囲:
Value
$1.02
$1.09
1週間の範囲:
Value
$1.02
$1.375
52週間の値動き範囲:
Value
$0.4227
$1.928

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1196)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
137
Name
Twitter
@nektarnews
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

NKTR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR 1.03 194.60M 90.12M -276.06M -193.47M -1.63
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
04:03 AM

Nektar presents preclinical data on NKTR-422 at ACR conference - TipRanks

04:03 AM
pulisher
03:30 AM

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - Longview News-Journal

03:30 AM
pulisher
Nov 14, 2024

Eventide Asset Management's Strategic Acquisition of Nektar Ther - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Reduces Stake in Nektar Therapeutics - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Multiple Catalysts Ahead For Nektar Therapeutics (NASDAQ:NKTR) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 11, 2024

NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance

Nov 11, 2024
pulisher
Nov 10, 2024

Nektar Therapeutics to sell Alabama facility to Ampersand - MSN

Nov 10, 2024
pulisher
Nov 10, 2024

NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC - Targeted Oncology

Nov 10, 2024
pulisher
Nov 10, 2024

Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Canada Finance

Nov 10, 2024
pulisher
Nov 09, 2024

Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024
pulisher
Nov 09, 2024

Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Nektar Therapeutics progresses with key clinical studies By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

Nektar Therapeutics (NKTR) Quarterly 10-Q Report - Quartz

Nov 08, 2024
pulisher
Nov 08, 2024

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Nektar reports NKTR-255 boosts lymphocyte recovery By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Nektar: Q3 Earnings Snapshot - The Washington Post

Nov 08, 2024
pulisher
Nov 08, 2024

Nektar Therapeutics Reports Stable Q3 Earnings for 2024 - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Nektar Therapeutics Q3 2024 Earnings: Revenue Surpasses Estimate - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c - StreetInsider.com

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar Therapeutics Narrows Losses, Sells Manufacturing Facility for $90M in Q3 | NKTR Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar releases promising phase 2 results for NKTR-255 in lymphopenia - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more - MM+M Online

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar reports NKTR-255 boosts lymphocyte recovery - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar Therapeutics (NKTR) and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 - StreetInsider.com

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar's NKTR-255 Shows Breakthrough Results in Cancer Treatment Study with MD Anderson | NKTR Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook By GuruFocus - Investing.com Canada

Nov 07, 2024
pulisher
Nov 06, 2024

Nektar Therapeutics to Participate in Upcoming Investor Conferences - Longview News-Journal

Nov 06, 2024
pulisher
Nov 06, 2024

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Ampersand’s Acquisition of a Nektar’s Manufacturing Facility and Reagent Supply Business - Global Legal Chronicle

Nov 05, 2024
pulisher
Nov 05, 2024

Nektar sells its PEGylation reagent manufacturing business - The Pharma Letter

Nov 05, 2024
pulisher
Nov 05, 2024

Nektar divests manufacturing site and reagent arm for $90M - Endpoints News

Nov 05, 2024
pulisher
Nov 05, 2024

Nektar announces agreement to sell Alabama manufacturing facility and reagent supply business - MSN

Nov 05, 2024
pulisher
Nov 04, 2024

NKTRNektar Therapeutics Latest Stock News & Market Updates - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Benzinga

Nov 04, 2024
pulisher
Nov 04, 2024

Nektar pads wallet with $90M manufacturing plant sale to Ampersand - FiercePharma

Nov 04, 2024
pulisher
Nov 04, 2024

Nektar divests Alabama facility to Ampersand for $90 million By Investing.com - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Nektar Therapeutics Sells Manufacturing Facility for $90M - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Nektar divests Alabama facility to Ampersand for $90 million - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Piper Sandler - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Nektar Therapeutics (NKTR) to Sell Commercial PEGylation Reagent Manufacturing Business in Alabama - StreetInsider.com

Nov 04, 2024
pulisher
Nov 04, 2024

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Piper Sandler Starts Nektar Therapeutics (NKTR) at Overweight - StreetInsider.com

Nov 04, 2024
pulisher
Nov 03, 2024

Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics for $90 million. - Marketscreener.com

Nov 03, 2024
pulisher
Nov 01, 2024

Nektar Therapeutics (NKTR) Stock Surges Amidst Mixed Financials - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Nektar Therapeutics (NKTR) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets - Longview News-Journal

Oct 31, 2024

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
大文字化:     |  ボリューム (24 時間):